Glial cell line-derived neurotrophic factor in the vitreous of patients with proliferative diabetic retinopathy.

Glial cell line–derived neurotrophic factor (GDNF) belongs to the neurotrophic factor family. GDNF functions are not restricted to neurons but are also implicated in glial cell development (1). We observed high expression levels of GDNF receptor family α-component 2 (GFRα2) in epiretinal membranes (ERMs) in proliferative diabetic retinopathy (PDR), indicating the involvement of GFRα2 in ERM formation in PDR (2). Here, we examined the vitreous of patients with PDR for the presence of GDNF. We assayed GDNF levels in …

[1]  R. Collins,et al.  Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). , 2005, Diabetes care.

[2]  M. Kholeif.  C-reactive protein for cardiovascular risk assessment. , 2005, Diabetes care.

[3]  E. Ipp,et al.  Point: Self-monitoring of blood glucose in type 2 diabetic patients not receiving insulin: the sanguine approach. , 2005, Diabetes care.

[4]  L. Bouter,et al.  Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review. , 2005, Diabetes care.

[5]  S. Del Prato,et al.  Use of Insulin Glargine During the First Weeks of Pregnancy in Five Type 1 Diabetic Women , 2022 .

[6]  M. Davidson,et al.  The effect of self monitoring of blood glucose concentrations on glycated hemoglobin levels in diabetic patients not taking insulin: a blinded, randomized trial. , 2005, The American journal of medicine.

[7]  N. Wong,et al.  Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein. , 2005, Diabetes care.

[8]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[9]  Paul M Ridker,et al.  Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? , 2004, Circulation.

[10]  Morris J. Brown,et al.  British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary , 2004, BMJ : British Medical Journal.

[11]  S. Haffner,et al.  Central adiposity determines prevalence differences of the metabolic syndrome. , 2003, Obesity research.

[12]  P Drouin,et al.  Self-monitoring of blood glucose significantly improves metabolic control in patients with type 2 diabetes mellitus: the Auto-Surveillance Intervention Active (ASIA) study. , 2003, Diabetes & metabolism.

[13]  T. Harada,et al.  Potential role of glial cell line-derived neurotrophic factor receptors in Müller glial cells during light-induced retinal degeneration , 2003, Neuroscience.

[14]  A. Holstein,et al.  Use of insulin glargine during embryogenesis in a pregnant woman with Type 1 diabetes , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[15]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[16]  S. Heymsfield,et al.  Relationships in men of sex hormones, insulin, adiposity, and risk factors for myocardial infarction. , 2003, Metabolism: clinical and experimental.

[17]  S. Priori,et al.  2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. , 2003, Journal of hypertension.

[18]  D. Berman,et al.  The metabolic syndrome, diabetes, and subclinical atherosclerosis assessed by coronary calcium. , 2003, Journal of the American College of Cardiology.

[19]  D. Feig,et al.  Transfer of insulin lispro across the human placenta: in vitro perfusion studies. , 2003, Diabetes care.

[20]  Sidney C. Smith,et al.  MARKERS OF INFLAMMATION AND CARDIOVASCULAR DISEASE: APPLICATION TO CLINICAL AND PUBLIC HEALTH PRACTICE: A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION AND THE AMERICAN HEART ASSOCIATION , 2003 .

[21]  Nancy R Cook,et al.  C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women , 2003, Circulation.

[22]  G. Mertes,et al.  Meal-related structured self-monitoring of blood glucose: effect on diabetes control in non-insulin-treated type 2 diabetic patients. , 2002, Diabetes care.

[23]  J. McNeill,et al.  Relationship among hyperinsulinemia, insulin resistance, and hypertension is dependent on sex. , 2002, American journal of physiology. Heart and circulatory physiology.

[24]  J. Devlin,et al.  Use of insulin glargine during pregnancy in a type 1 diabetic woman. , 2002, Diabetes care.

[25]  K. Ohtsuka,et al.  Neurotrophic factor receptors in epiretinal membranes after human diabetic retinopathy. , 2002, Diabetes care.

[26]  T. Hofmann,et al.  Evaluation of the Reproductive Toxicity and Embryotoxicity of Insulin Glargine (LANTUS) in Rats and Rabbits , 2002, International journal of toxicology.

[27]  K. Friday,et al.  Conjugated Equine Estrogen Improves Glycemic Control and Blood Lipoproteins in Postmenopausal Women With Type 2 Diabetes , 2001 .

[28]  J. Westerbacka,et al.  Effect of estrogen replacement therapy on insulin sensitivity of glucose metabolism and preresistance and resistance vessel function in healthy postmenopausal women. , 2000, The Journal of clinical endocrinology and metabolism.

[29]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[30]  E. Barrett-Connor,et al.  Sex differences in the association of endogenous sex hormone levels and glucose tolerance status in older men and women. , 2000, Diabetes care.

[31]  K. Unsicker,et al.  GDNF family members and their receptors: Expression and functions in two oligodendroglial cell lines representing distinct stages of oligodendroglial development , 1999, Glia.

[32]  J. Levy,et al.  Correct Homeostasis Model Assessment (HOMA) Evaluation Uses the Computer Program , 1998, Diabetes Care.

[33]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[34]  L. Niskanen,et al.  Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. , 1997, The Journal of clinical endocrinology and metabolism.

[35]  D. Muchmore,et al.  Self-monitoring of blood glucose in overweight type 2 diabetic patients , 1994, Acta Diabetologica.

[36]  E. DeLong,et al.  Impact of Glucose Self-Monitoring on Non-lnsulin-Treated Patients With Type II Diabetes Mellitus: Randomized Controlled Trial Comparing Blood and Urine Testing , 1990, Diabetes Care.

[37]  M. Laakso,et al.  Ischemic heart disease risk in postmenopausal women. Effects of estrogen use on glucose and insulin levels. , 1990, Arteriosclerosis.

[38]  G. Slama,et al.  Is glucose self-monitoring beneficial in non-insulin-treated diabetic patients? Results of a randomized comparative trial. , 1989, Diabete & metabolisme.

[39]  J. Challier,et al.  Effect of insulin on glucose uptake and metabolism in the human placenta. , 1986, The Journal of clinical endocrinology and metabolism.

[40]  N. Rifai,et al.  CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice Report From the Laboratory Science Discussion Group , 2004, Circulation.

[41]  I. Aoyama,et al.  An oral adsorbent ameliorates renal overload of indoxyl sulfate and progression of renal failure in diabetic rats. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[42]  L. Heinemann,et al.  Influence of continuous combined estradiol-norethisterone acetate preparations on insulin sensitivity in postmenopausal nondiabetic women. , 1999, Menopause.